|
1
|
Lewis VO: What’s new in musculoskeletal
oncology. J Bone Joint Surg Am. 89:1399–1407. 2007.
|
|
2
|
Iwamoto Y, Tanaka K, Isu K, et al:
Multiinstitutional phase II study of neoadjuvant chemotherapy for
osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop
Sci. 14:397–404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meyers PA, Schwartz CL, Krailo M, et al:
Osteosarcoma: a randomized, prospective trial of the addition of
ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and
high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee JW, Kim H, Kang HJ, et al: Clinical
characteristics and treatment results of pediatric osteosarcoma:
the role of high dose chemotherapy with autologous stem cell
transplantation. Cancer Res Treat. 40:172–177. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cho Y, Jung GH, Chung SH, et al: Long-term
survivals of stage IIB osteosarcoma: a 20-year experience in a
single institution. Clin Orthop Surg. 3:48–54. 2011.PubMed/NCBI
|
|
6
|
Tsuchiya H, Tomita K, Mori Y, et al:
Caffeine-assisted chemotherapy and minimized tumor excision for
nonmetastatic osteosarcoma. Anticancer Res. 18:657–666. 1998.
|
|
7
|
Bölling T, Schüller P, Distelmaier B, et
al: Perioperative high-dose rate brachytherapy using a bendy
applicator (flab): treatment results of 74 patients. Anticancer
Res. 28:3885–3890. 2008.PubMed/NCBI
|
|
8
|
Qi WX, He AN, Tang LN, et al: Evaluation
of pirarubicin-cisplatin chemotherapy in the treatment for
refractory and recurrent high-grade osteosarcoma: experience of a
single institute. Med Oncol. 29:2229–2233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Futani H, Fukunaga S, Tsukamoto Y, et al:
Small cell osteosarcoma successfully treated by high-dose
ifosfamide and methotrexate, combined with carboplatin and
pirarubicin. Anticancer Res. 32:965–971. 2012.PubMed/NCBI
|
|
10
|
Zhao H, Yao Y, Wang Z, et al: Therapeutic
effect of pirarubicin-based chemotherapy for osteosarcoma patients
with lung metastasis. J Chemother. 22:119–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shinozaki T, Watanabe H, Yanagawa T, et
al: Pirarubicin-based versus doxorubicin-based osteosarcoma
chemotherapy. Ann Pharmacother. 36:996–999. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He A, Qi W, Huang Y, et al: Comparison of
pirarubicin-based versus gemcitabine-docetaxel chemotherapy for
relapsed and refractory osteosarcoma: a single institution
experience. Int J Clin Oncol. 18:498–505. 2013. View Article : Google Scholar
|
|
13
|
Niitsu N, Yamazaki J, Nakayama M and Umeda
M: Pirarubicin-induced myocardial damage in elderly patients with
non-Hodgkin’s lymphoma. Nihon Ronen Igakkai Zasshi. 35:358–362.
1998.(In Japanese).
|
|
14
|
García MG, Alaniz LD, Cordo Russo RI, et
al: PI3K/Akt inhibition modulates multidrug resistance and
activates NF-kappaB in murine lymphoma cell lines. Leuk Res.
33:288–296. 2009.PubMed/NCBI
|
|
15
|
Yu HG, Ai YW, Yu LL, et al:
Phosphoinositide 3-kinase/Akt pathway plays an important role in
chemoresistance of gastric cancer cells against etoposide and
doxorubicin induced cell death. Int J Cancer. 122:433–443. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie X, Tang B, Zhou J, et al: Inhibition
of the PI3K/Akt pathway increases the chemosensitivity of gastric
cancer to vincristine. Oncol Rep. 30:773–782. 2013.PubMed/NCBI
|
|
17
|
Wu D, Tao J, Xu B, et al:
Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses
proliferation and sensitizes doxorubicin chemotherapy in bladder
cancer cells. Urol Int. 87:105–113. 2011. View Article : Google Scholar
|
|
18
|
Kwon O, Kim KA, Kim SO, et al: NF-kappaB
inhibition increases chemosensitivity to trichostatin A-induced
cell death of Ki-Ras-transformed human prostate epithelial cells.
Carcinogenesis. 27:2258–2268. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fu ZY, Lv JH, Ma CY, et al: Tissue
inhibitor of metalloproteinase-1 decreased chemosensitivity of
MDA-435 breast cancer cells to chemotherapeutic drugs through the
PI3K/AKT/NF-κB pathway. Biomed Pharmacother. 65:163–167.
2011.PubMed/NCBI
|
|
20
|
Bacci G, Forni C, Longhi A, et al: Local
recurrence and local control of non-metastatic osteosarcoma of the
extremities: a 27-year experience in a single institution. J Surg
Oncol. 96:118–123. 2007.PubMed/NCBI
|
|
21
|
Jawad MU, Cheung MC, Clarke J, et al:
Osteosarcoma: improvement in survival limited to high-grade
patients only. J Cancer Res Clin Oncol. 137:597–607. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferrari S, Smeland S, Mercuri M, et al;
Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy
with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and
doxorubicin for patients with localized osteosarcoma of the
extremity: a joint study by the Italian and Scandinavian Sarcoma
Groups. J Clin Oncol. 23:8845–8852. 2005. View Article : Google Scholar
|
|
23
|
Wu D, Tao J, Xu B, et al:
Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses
proliferation and sensitizes doxorubicin chemotherapy in bladder
cancer cells. Urol Int. 87:105–113. 2011. View Article : Google Scholar
|
|
24
|
Semba S, Itoh N, Ito M, et al: The in
vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone
(LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase,
in human colon cancer cells. Clin Cancer Res. 8:1957–1963.
2002.PubMed/NCBI
|
|
25
|
Hu L, Zaloudek C, Mills GB, et al: In vivo
and in vitro ovarian carcinoma growth inhibition by a
phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer
Res. 6:880–886. 2000.PubMed/NCBI
|
|
26
|
Chen Z, Yang L, Liu Y, et al: LY294002 and
Rapamycin promote coxsackievirus-induced cytopathic effect and
apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway. Mol
Cell Biochem. 385:169–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meesungnoen J, Jay-Gerin JP and
Mankhetkorn S: Relation between MDR1 mRNA levels, resistance
factor, and the efficiency of P-glycoprotein-mediated efflux of
pirarubicin in multidrug-resistant K562 sublines. Can J Physiol
Pharmacol. 80:1054–1063. 2002. View
Article : Google Scholar
|
|
28
|
Liang J, Ge F, Guo C, et al: Inhibition of
PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug
resistance in gastric cancer cells. FEBS J. 276:685–694. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Imai Y, Yamagishi H, Ono Y and Ueda Y:
Versatile inhibitory effects of the flavonoid-derived PI3K/Akt
inhibitor, LY294002, on ATP-binding cassette transporters that
characterize stem cells. Clin Transl Med. 1:242012. View Article : Google Scholar
|
